Skip to main content

Day: March 5, 2024

CECO Environmental Reports Fourth Quarter and Full Year 2023 Results

Reports Q4 and Full Year Earnings with Multiple Financial RecordsCompany Raises Full Year 2024 Guidance DALLAS, March 05, 2024 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the fourth quarter and full year results of 2023. Highlights for the Quarter(1)Orders of $128.3 million Backlog of $370.9 million, up 19 percent Revenue of $153.7 million, up 32 percent Net income of $3.9 million, down 53 percent; non-GAAP net income of $10.1 million, up 36 percent GAAP EPS (diluted) of $0.11; non-GAAP EPS (diluted) of $0.28 Adjusted EBITDA of $19.4 million, up 49 percent Free cash flow of $12.2 million, up 36 percentHighlights...

Continue reading

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628 study in epilepsy patients with photo-paroxysmal response (PPR) expected in 1Q 2024; preliminary analysis of 15 mg cohort exceeded expectations Tolerability and efficacy results from Part 1 of the EMBRAVE study of elsunersen were presented at the American Epilepsy Society 2023 Annual Meeting, showing 43% median reduction in seizures; received PRIME designation from the European Medicines Agency for the treatment of SCN2A gain-of-function developmental and epileptic encephalopathy (DEE) Announced licensing partnership with Tenacia Biotechnology to develop and commercialize...

Continue reading

Form 8.3 – [SMART METERING SYSTEMS PLC] – 04 03 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree SMART METERING SYSTEMS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [LXi REIT PLC] – 04 03 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LXi REIT PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [LONDONMETRIC PROPERTY PLC] – 04 03 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LONDONMETRIC PROPERTY PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Ladybug Announces Acquisition of E-Commerce Generating $2.4 Million Annual Revenue

TULSA, Okla., March 05, 2024 (GLOBE NEWSWIRE) — Ladybug Resource Group, Inc. (OTC PINK: LBRG) (“Ladybug” or the “Company”), through its subsidiary Growhouse Nutraceuticals Ltd., is actively bolstering its revenue with strategic acquisitions in the health and wellness domain. The recent acquisition of https://nutra55.com from Lifespot Wellness Ltd. is a testament to this strategy. Tamara Maxfield, B.A., CEO of Growhouse, commented on the growth trajectory, “2023 was a year of exceptional growth for us. This new acquisition is poised to substantially elevate our market position, with an estimated $2.4 million yearly revenue. It’s a move that aligns with our commitment to delivering excellent value to our customers and stakeholders.” Looking forward to 2024, Tamara Maxfield emphasizes Growhouse’s...

Continue reading

Vivid Seats Reports Fourth Quarter Results and Authorizes New Share Repurchase Program

Finishes Transformational 2023 with Foundation for Durable Growth CHICAGO, March 05, 2024 (GLOBE NEWSWIRE) — Vivid Seats Inc. (NASDAQ: SEAT) (“Vivid Seats” or “we”), a leading marketplace that utilizes its technology platform to connect millions of buyers with thousands of ticket sellers across hundreds of thousands of events each year, today provided financial results for the full year and fourth quarter ended December 31, 2023. “In 2023 we grew top and bottom line by nearly 25%, significantly expanded our TAM through strategic acquisitions, and executed against our objective of being the marketplace of choice for both sellers and buyers,” said Stan Chia, Vivid Seats CEO. “We also added incremental products such as Skybox Drive on the seller side while building brand awareness and affinity on the buyer side with...

Continue reading

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company’s pipeline of mRNA cell therapies for the treatment of autoimmune diseases GAITHERSBURG, Md., March 05, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced its plans to transition its corporate headquarters to Frederick, Maryland. The approximately 20,000 square foot state-of-the-art current good manufacturing practice (cGMP) compliant facility has clinical and commercial manufacturing scale capabilities designed to support the Company’s maturing pipeline of innovative mRNA cell therapies for the treatment of autoimmune diseases. “Our new headquarters and manufacturing facility will provide us...

Continue reading

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results

Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 BOSTON and ROLLE, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for its fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial HighlightsRevenue grew 27% year-over-year to $17.0 million; Constant currency revenue excluding COVID-related revenue also grew 27% year-over-year Gross margins were 70% on a reported basis and 73% on an adjusted basis Operating loss was $18.9 million on a reported basis and $13.3 million on an adjusted basis Change in cash and cash equivalents and term deposits (cash burn) improved 11% year-over-year...

Continue reading

Crawford United Corporation Announces Fourth Quarter and Full Year 2023 Results

Earnings per share of $3.77 for the year and $0.91 for the quarter Sales of $143.9 million for the year, an increase of 12.6% Net income of $13.3 million for the year, an increase of 101.5% EBITDA As Defined1 of $25.6 million for the year, an increase of 64.1%CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) — Crawford United Corporation (OTC: CRAWA), a growth-oriented holding company serving diverse markets, today reported results for the quarter and year ended December 31, 2023. For the quarter ended December 31, 2023, sales were $33.8 million compared with $32.7 million in the same period in 2022, an increase of 3.4%. In the quarter, the Company recorded operating income of $3.4 million compared with operating income of $2.8 million in the same period of the prior year, an increase of 21.4%. Net income was $3.2 million, or $0.91...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.